PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy

Biochemical and Biophysical Research Communications

Volumn 477, Issue 2, 2016, Pages 277-282

  Park, Ji Hoon ^a   Kim, Keun Pil ^b   Ko, Jeong Jae ^a   Park, Kyung Soon ^a  

^a CHA University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Autophagy; Doxorubicin; ELK3; MDA MB 231 cell line; PI3K Akt

Indexed keywords

ATG8 PROTEIN; BIOLOGICAL MARKER; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN AGGREGATE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK3; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; ELK3 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84976609228     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.06.057     Document Type: Article

References (38)

1. [1] Giovane, A., Pintzas, A., Maira, S.M., Sobieszczuk, P., Wasylyk, B., Net, a new ets transcription factor that is activated by Ras. Genes Dev. 8 (1994), 1502–1513.
2. [2] Ducret, C., Maira, S.M., Lutz, Y., Wasylyk, B., The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades. Oncogene 19 (2000), 5063–5072.
3. [3] Heo, S.H., Cho, J.Y., ELK3 suppresses angiogenesis by inhibiting the transcriptional activity of ETS-1 on MT1-MMP. Int. J. Biol. Sci. 10 (2014), 438–447.
4. [4] Heo, S.H., Lee, J.Y., Yang, K.M., Park, K.S., ELK3 expression correlates with cell migration, invasion, and membrane type 1-matrix metalloproteinase expression in MDA-MB-231 breast cancer cells. Gene Expr. 16 (2015), 197–203.
5. [5] Ducret, C., Maira, S.M., Dierich, A., Wasylyk, B., The net repressor is regulated by nuclear export in response to anisomycin, UV, and heat shock. Mol. Cell Biol. 19 (1999), 7076–7087.
6. [6] Sloan, K.A., et al. Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines. Carcinogenesis 30 (2009), 1433–1442.
7. [7] Yang, H., Schramek, D., Adam, R.C., Keyes, B.E., Wang, P., Zheng, D., Fuchs, E., ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. Elife, 4, 2015.
8. [8] Rabinowitz, J.D., White, E., Autophagy and metabolism. Science 330 (2010), 1344–1348.
9. [9] Sui, X., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis., 4, 2013, e838.
10. [10] Nagelkerke, A., Bussink, J., Geurts-Moespot, A., Sweep, F.C., Span, P.N., Therapeutic targeting of autophagy in cancer. part II: pharmacological modulation of treatment-induced autophagy. Semin. Cancer Biol. 31 (2015), 99–105.
11. [11] Mahalingam, D., et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10 (2014), 1403–1414.
12. [12] Rangwala, R., et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10 (2014), 1391–1402.
13. [13] Rangwala, R., et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10 (2014), 1369–1379.
14. [14] Rosenfeld, M.R., et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10 (2014), 1359–1368.
15. [15] Vogl, D.T., et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10 (2014), 1380–1390.
16. [16] Phillips, A.R., Suttangkakul, A., Vierstra, R.D., The ATG12-conjugating enzyme ATG10 Is essential for autophagic vesicle formation in Arabidopsis thaliana. Genetics 178 (2008), 1339–1353.
17. [17] Maiuri, M.C., Tasdemir, E., Criollo, A., Morselli, E., Vicencio, J.M., Carnuccio, R., Kroemer, G., Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 16 (2009), 87–93.
18. [18] Meijer, A.H., van der Vaart, M., DRAM1 promotes the targeting of mycobacteria to selective autophagy. Autophagy 10 (2014), 2389–2391.
19. [19] Shukla, S., et al. Methylation silencing of ULK2, an autophagy gene, is essential for astrocyte transformation and tumor growth. J. Biol. Chem. 289 (2014), 22306–22318.
20. [20] Yuan, J., Zhang, Y., Sheng, Y., Fu, X., Cheng, H., Zhou, R., MYBL2 guides autophagy suppressor VDAC2 in the developing ovary to inhibit autophagy through a complex of VDAC2-BECN1-BCL2L1 in mammals. Autophagy 11 (2015), 1081–1098.
21. [21] Herpin, A., Englberger, E., Zehner, M., Wacker, R., Gessler, M., Schartl, M., Defective autophagy through epg5 mutation results in failure to reduce germ plasm and mitochondria. FASEB J. 29 (2015), 4145–4161.
22. [22] Sarkar, S., et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. Cell Rep. 5 (2013), 1302–1315.
23. [23] Swaminathan, B., Goikuria, H., Vega, R., Rodriguez-Antiguedad, A., Lopez Medina, A., Freijo Mdel, M., Vandenbroeck, K., Alloza, I., Autophagic marker MAP1LC3B expression levels are associated with carotid atherosclerosis symptomatology. PLoS One, 9, 2014, e115176.
24. [24] Tatti, M., Motta, M., Di Bartolomeo, S., Cianfanelli, V., Salvioli, R., Cathepsin-mediated regulation of autophagy in saposin C deficiency. Autophagy 9 (2013), 241–243.
25. [25] Tambe, Y., Yamamoto, A., Isono, T., Chano, T., Fukuda, M., Inoue, H., The drs tumor suppressor is involved in the maturation process of autophagy induced by low serum. Cancer Lett. 283 (2009), 74–83.
26. [26] Iwai-Kanai, E., Yuan, H., Huang, C., Sayen, M.R., Perry-Garza, C.N., Kim, L., Gottlieb, R.A., A method to measure cardiac autophagic flux in vivo. Autophagy 4 (2008), 322–329.
27. [27] Arico, S., Petiot, A., Bauvy, C., Dubbelhuis, P.F., Meijer, A.J., Codogno, P., Ogier-Denis, E., The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 276 (2001), 35243–35246.
28. [28] Lindmo, K., Stenmark, H., Regulation of membrane traffic by phosphoinositide 3-kinases. J. Cell Sci. 119 (2006), 605–614.
29. [29] Lum, J.J., DeBerardinis, R.J., Thompson, C.B., Autophagy in metazoans: cell survival in the land of plenty. Nat. Rev. Mol. Cell Biol. 6 (2005), 439–448.
30. [30] Debnath, J., The multifaceted roles of autophagy in tumors-implications for breast cancer. J. Mammary Gland. Biol. Neoplasia 16 (2011), 173–187.
31. [31] Amaravadi, R.K., Yu, D., Lum, J.J., Bui, T., Christophorou, M.A., Evan, G.I., Thomas-Tikhonenko, A., Thompson, C.B., Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117 (2007), 326–336.
32. [32] Guo, J.Y., Xia, B., White, E., Autophagy-mediated tumor promotion. Cell 155 (2013), 1216–1219.
33. [33] Mathew, R., Karantza-Wadsworth, V., White, E., Role of autophagy in cancer. Nat. Rev. Cancer 7 (2007), 961–967.
34. [34] Guan, F., Ding, Y., Zhang, Y., Zhou, Y., Li, M., Wang, C., Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation. PLoS One, 11, 2016, e0146553.
35. [35] Albert, J.M., Kim, K.W., Cao, C., Lu, B., Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 5 (2006), 1183–1189.
36. [36] Deng, M., Wang, J., Chen, Y., Zhang, L., Liu, D., Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Anticancer Drugs 26 (2015), 422–427.
37. [37] Harfouche, R., Basu, S., Soni, S., Hentschel, D.M., Mashelkar, R.A., Sengupta, S., Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 12 (2009), 325–338.
38. [38] Li, J.P., et al. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des. Devel Ther. 9 (2015), 1627–1652.